1241 PROSPECTIVE STUDY UROSCREEN - HIGH VALIDITY OF URINARY TUMOUR MARKERS IN EARLY DIAGNOSIS OF BLADDER CANCER IN A HIGH-RISK POPULATION
2011-04-01

You have accessJournal of UrologyBladder Cancer: Detection and Screening1 Apr 20111241 PROSPECTIVE STUDY UROSCREEN - HIGH VALIDITY OF URINARY TUMOUR MARKERS IN EARLY DIAGNOSIS OF BLADDER CANCER IN A HIGH-RISK POPULATION Severine Huber, Feil Gerhard, Sievert Karl-Dietrich, Nasterlack Michael, Gabriele Leng, Beate Pesch, Dirk Taeger, Thomas Mayer, Thomas Bruening, and Arnulf Stenzl Severine HuberSeverine Huber Tuebingen, Germany More articles by this author , Feil GerhardFeil Gerhard Tuebingen, Germany More articles by this author , Sievert Karl-DietrichSievert Karl-Dietrich Tuebingen, Germany More articles by this author , Nasterlack MichaelNasterlack Michael Ludwigshafen, Germany More articles by this author , Gabriele LengGabriele Leng Leverkusen, Germany More articles by this author , Beate PeschBeate Pesch Bochum, Germany More articles by this author , Dirk TaegerDirk Taeger Bochum, Germany More articles by this author , Thomas MayerThomas Mayer Ludwigshafen, Germany More articles by this author , Thomas BrueningThomas Bruening Bochum, Germany More articles by this author , and Arnulf StenzlArnulf Stenzl Tuebingen, Germany More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2011.02.912AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES UroScreen is a prospective study for early diagnosis of bladder cancer in 1,772 chemical workers with former exposure to aromatic amines. The aim of the study is to assess the predictive values of the urine-based tumour marker tests Uro¬Vysion, NMP22, and urine cytology for bladder cancer screening. Results from observations between September 2003 and June 2010 are presented. METHODS UroScreen is going to be conducted as extended screening program of annual preventive medical checkups for early diagnosis of bladder cancer in high-risk populations according to the guidelines of the German Social Accident Insurance. As of June 2010, 1,611 active and former chemical workers at the age of 58 (25–86) years formerly exposed to tumourigenic aromatic amines were enrolled. All subjects gave informed consent. 7,252 preventive medical checkups were performed. Urine samples were collected for urine cytology, chromosomal aberrations by the UroVysion test, and determination of nuclear matrix protein 22 (NMP22) by the quantitative NMP22 immunoassay. If ≥ 1 test was positive (UroVysion > 3 polyploid cells, NMP22 > 10 U/ml), cystoscopy was recommended. RESULTS Among 1,611 persons enrolled in a total of 7,252 annual investigations, 348 checkups revealed ≥ 1 positive tumour marker test. Urine cytology, UroVysion, and NMP22, were positive in 15, 81, and 225 checkups, respectively. UroVysion in combination with cytology and/or NMP22 was positive in another 27 checkups. Cystoscopy was performed in 230 subjects on a voluntary basis. 12 bladder carcinomas (2 Cis, 5 pTa, 2 pT1, 1 pT1+Cis, 1 pT2, 1 pT3b) and 2 bladder papillomas were detected. Microhaematuria was diagnosed in 7 (50%) of these tumour patients only. Another 5 bladder cancers (2 pTa, 2 pT1, 1 pT1+Cis) and another papilloma were detected in subjects in whom cytology, UroVysion, and NMP22 were negative. CONCLUSIONS The results underline the diagnostic validity of tumour marker tests for early diagnosis of bladder cancer in asymptomatic persons with high risk for bladder cancer. The combination of cell-based (UroVysion, cytology) and protein-based (NMP22) markers may improve sensitivity and specificity of urine-based tumour markers in screening high-risk populations for bladder cancer. © 2011 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 185Issue 4SApril 2011Page: e497 Advertisement Copyright & Permissions© 2011 by American Urological Association Education and Research, Inc.MetricsAuthor Information Severine Huber Tuebingen, Germany More articles by this author Feil Gerhard Tuebingen, Germany More articles by this author Sievert Karl-Dietrich Tuebingen, Germany More articles by this author Nasterlack Michael Ludwigshafen, Germany More articles by this author Gabriele Leng Leverkusen, Germany More articles by this author Beate Pesch Bochum, Germany More articles by this author Dirk Taeger Bochum, Germany More articles by this author Thomas Mayer Ludwigshafen, Germany More articles by this author Thomas Bruening Bochum, Germany More articles by this author Arnulf Stenzl Tuebingen, Germany More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...